The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate-Reference-Cited by-同舟云学术

The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate

Published:2023-01-31 Issue:1 Volume:97 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

McGinnes Cullen Lori¹,Luo Bin²,Wen Zhiyun³,Zhang Lan³,Durr Eberhard³,Morrison Trudy G.¹^ORCID

Affiliation:

1. Department of Microbiology and Physiological Systems, Program in Immunology and Microbiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA

2. Pharmacology, Merck & Co., Inc., West Point, Pennsylvania, USA

3. Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA

Abstract

Respiratory syncytial virus (RSV) results in significant disease in infants, young children, and the elderly. Thus, development of an effective vaccine for these populations is a priority.

Funder

HHS | National Institutes of Health

Merck

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.01900-22

Reference64 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

2. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis